Technology

Core Technology

Core Technology

Immunologix’s novel platform technology transforms naïve B-cells into fully human IgG monoclonal antibodies targeting any antigen in an in vitro setting. While there are a number of humanized in vitro techniques that produce antibodies, never before has the production of fully human antibodies been achieved in vitro from naïve B-cells. The alternative techniques that produce Hybridomas, chimeric antibodies and humanized antibodies do not result in truly human antibodies and often lead to obscure immune reactions such as toxicity and serum sickness following delivery.

Immunologix Proprietary Mixture

Key Technology Attributes

  • Completely in vitro process producing fully-human antibodies with high binding affinity
  • First technology where naïve B-cells transformed in an in vitro setting, yielding fully-human antibodies
  • No host immunization required
  • Fully human antibody delivered to client within 145 days versus 550 days for delivery of a humanized antibody
  • Significantly lower production cost is over one million dollars less than first generation mAbs
  • Immunologix controls exclusive patent rights to this technology platform  

Target Selection

Identifying novel antigen targets typically involves a range of technologies including genome-wide expression profiling, proteomics, bioinformatics and the use of transgenic mice. Once a new target has been identified and its relevance to disease has been confirmed, current technologies can at best then begin the humanization process. The proprietary monoclonal antibody Immunologix platform generates fully-human drug candidates that undergo selection based on their ability to precisely modulate the function of a specific target.

Immunologix technology has the potential to generate high binding affinity human antibodies of all isotypes and subclasses that theoretically recognize all antigen structures. We have also been able to create large panels of monoclonal antibodies to many medically relevant antigens. For any given antigen target, the ability to select a product candidate from a pool of multiple antibody isotopes is crucial for selection of the optimal product for development.

Novel Antibody Production Method

The Immunologix Antibody Production system utilizes the natural in vivo random differentiation of naïve B-cells, bypassing both positive and negative selection, producing countless antibodies. This novel in vitro system produces human B-cells (and thus antibodies) from antigen-naïve B-cells isolated from human tonsils or whole blood. It is important to note that these patients are unexposed to the antigen in question, and lacks the production of the antibodies in question.

The (simplified) steps are as follows:

  1. Human naïve B-cells are isolated from tonsils or whole blood
  2. Using a proprietary method, cells are immortalized, inducing infinite IgG and a complete repertoire of, theoretically, every possible combination of antibodies
  3. Cells are screened using a soluble protein/peptide
  4. Immortalized B-cells can be cryogenically stored, or cultivated to continuously produce specific therapeutic antibodies at a low cost and reliability that exceeds all other current products